West Pharmaceutical Services, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Investigation Details

On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts’ expectations. Management attributed the low guidance to currency headwinds, operating expenses and “glucose monitoring transition.” Analysts expressed shock and disappointment at the Company’s full year 2025 outlook.

Following this news, WST’s stock price fell by $123.17 per share, or approximately 38% to close at $199.11 per share.